Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101

A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients With Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101

PausedPhase 2Relapsing and progressiveNCT049095022022-000253-92

What it found

Still running

No result yet.

Reason given: Temporary recruitment pause to re-assess the protocol design, specifically the eligibility criteria

What was tested

Treatment tested

  • EHP-101 25 mg OD
  • Etrinabdione
  • EHP-101 50 mg OD

What it measured

Main measures

  • Incidence and severity of Treatment Emergent Adverse Events

    168 days (24 weeks)

    Safety

Other measures (13)

  • Brain lesion activity measured by MRI

    168 days (24 weeks)

    MRI lesions

  • Disease progression measured by MS Functional Composite (MSFC)

    168 days (24 weeks)

    Disability progressionThinking and memoryWalking and mobilityArm and hand function

  • Disease progression measured by Expanded Disability Status Scale (EDSS)

    168 days (24 weeks)

    Disability progressionFatigueBladder, bowel and sexual function

  • Disease progression measured by Symbol Digit Modalities Test (SDMT)

    168 days (24 weeks)

    Thinking and memory

  • Disability status measured by MS Functional Composite (MSFC)

    168 days (24 weeks)

    Disability progressionThinking and memoryWalking and mobilityArm and hand function

  • Disability status measured by Expanded Disability Status Scale (EDSS)

    168 days (24 weeks)

    Disability progressionFatigueBladder, bowel and sexual function

  • Disability status measured by Symbol Digit Modalities Test (SDMT)

    168 days (24 weeks)

    Thinking and memory

  • Time to first relapse

    168 days (24 weeks)

    Relapses

  • Preliminary Annualized Relapse Rate (ARR)

    168 days (24 weeks)

    Relapses

  • Percent of patients who experience a relapse

    168 days (24 weeks)

    Relapses

Who could take part

Relapsing and progressive · 18 to 55 · EDSS 0 to 6.0

Show the full criteria

Inclusion criteria

* Male and female adults aged 18 to 55 years at the time of consent; * Confirmed diagnosis of MS according to the revised 2017 McDonald criteria; * Relapsing forms of MS (RMS) including Relapsing-Remitting MS (RRMS) and active Secondary Progressive MS (SPMS); * Patients must have experienced at least 1 of the following within 12 months prior to Visit 1: an acute clinical relapse, gadolinium-enhancing T1 lesions on brain or spinal cord magnetic resonance imaging (MRI), or new T2 lesion(s) on brain or spinal cord MRI; * Neurologically stable with no evidence of clinical relapse of MS or corticosteroid treatment within 28 days prior to the first investigational product administration; * Naïve to prior MS treatment or discontinuing current MS treatment due to (1) intolerability, (2) laboratory abnormalities, (3) current treatment perceived by the patient to be ineffective, (4) patient preference, or (5) based on investigator judgement to switch MS therapy; * An EDSS score of 0 to 6.0 (inclusive) at screening and enrolment visit; * Willing and able to provide informed consent and capable of understanding and complying with the protocol.

Exclusion criteria

* Primary progressive MS (PPMS) or non-active secondary progressive MS (SPMS); * Relapse during the 28 days prior to first investigational product administration; * Total lymphoid irradiation, T-cell or T-cell receptor vaccination, total body irradiation, or total lymphoid irradiation at any time; * Treatment with alemtuzumab, mitoxantrone, cyclophosphamide or cladribine at any time; * MS treatment that may impact the efficacy or safety assessment defined as follows: 1. 52 weeks or less prior to first investigational product administration: Immunosuppressant agents (e.g., cyclosporine, methotrexate, mycophenolate) 2. 36 weeks or less prior to first investigational product administration: CD20 depletion therapies such as rituximab, ocrelizumab, ofatumumab or others. Condition for inclusion of patients who had CD20 depletion therapies more than 36 weeks prior to the first investigational product administration: may only be included if there is no clinically relevant B cell depletion and possible safety risk to patients based on the Investigator's opinion. 3. 12 weeks or less prior to first investigational product administration: natalizumab 4. 8 weeks or less prior to first investigational product administration: dimethyl-fumarate fingolimod 5. 4 weeks or less prior to first investigational product administration: corticosteroids intravenous immunoglobulin (IVIG) ozanimod, siponimod, or ponesimod glatiramer acetate interferons 6. 2 weeks or less prior to first investigational product administration: teriflunomide. Subject must exhibit no active agent in serum levels; cholestyramine or activated charcoal washout may be used to achieve this; * Any one of the following values for laboratory test at screening: 1. Haemoglobin \< 9 g/dL; 2. Neutrophils \< 1.0 x 10\^9/L; 3. Platelets \< 75 x 10\^9/L; 4. Serum transaminases > 2.0 x upper limit of normal; 5. Total bilirubin ≥ 1.5 x upper limit of normal; 6. Thyroid-stimulating hormone level >10% above of the upper limit of normal; 7. Estimated glomerular filtration rate ≤60 mL/min/1.73m2 (using the Cockcroft-Gault equation); 8. Lymphocytes \< 1 × 10\^9/L;

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).

Papers

    Loading reviews and guidelines…

    History

      1. Started

        Oct 2021

      2. Main results due

        Dec 2023

      3. Finished

        Apr 2024

      Assembled by software from public sources.